SBIR/STTR Research Award
SYSTEM FOR QUANTIFICATION OF CANCER GENE EXPRESSION
Award amount
$143,905Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- AMBION DIAGNOSTICS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
APPLICANT'S DESCRIPTION: Evaluating gene expression levels is crucial for
understanding cancer biology and identifying prognostic indicators of cancer. A
need exists for a mRNA quantification assay that combines superior sensitivity
with the simplicity and versatility that are not available from reverse
transcriptase-polymerase chain reaction (RT-PCR) or current
transcription-mediated amplification systems. The Split Promoter Amplification
Reaction (SPAR) and similar methods provide this unique combination of
attributes. Here, our goal is to evaluate the feasibility of using a novel,
isothermal, linear amplification technology for quantifying specific mRNAs in
complex RNA samples. Our specific aims will
(1) develop an assay with optimal sensitivity and specificity for
quantification of a specific mRNA in a total RNA sample and
(2) develop and optimize assays for quantification of multiple mRNAs in a total
RNA sample (multiplexing). We will produce a fast and inexpensive assay system,
for detecting and quantifying oncogenes and other genetic markers for cancer,
that is both sensitive and quantitative. Phase I will determine feasibility of
a product that will have high utility for cancer researchers who are
quantifying gene expression. The system will be adaptable for gene
quantification in numerous fields including immunology, development, and
infectious diseases and will be applicable in research and diagnostics.
PROPOSED COMMERCIAL APPLICATION:
Ambion, a leading supplier of products for RNA analysis and quantification, will initially market
a kit for the sensitive and specific detection and quantification of cancer genes. The technology
will be applicable for quantifying low levels of RNA in any research field including infectious
diseases, cancer research, immunology, developmental biology, and molecular biology. The
research will lead to new methods and applications of transcription-based amplification.
Phase II/III will see the development of diagnostic assays.
Technology keywords
Not reported